{"id":"arixtra-infusion","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding (major and minor)"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Elevated liver enzymes"}]},"_chembl":{"chemblId":"CHEMBL1201202","moleculeType":"Oligosaccharide","molecularWeight":"1508.27"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fondaparinux is a synthetic pentasaccharide that binds to antithrombin III, enhancing its ability to inactivate Factor Xa, a critical enzyme in the intrinsic and common pathways of blood coagulation. By blocking Factor Xa, it prevents the conversion of prothrombin to thrombin, thereby inhibiting clot formation without directly affecting thrombin itself. This selective mechanism provides anticoagulation with a predictable pharmacokinetic profile and subcutaneous bioavailability.","oneSentence":"ARIXTRA (fondaparinux) selectively inhibits Factor Xa in the coagulation cascade, preventing thrombin generation and blood clot formation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:42:55.767Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prophylaxis of venous thromboembolism in patients undergoing hip fracture surgery, hip replacement surgery, or knee replacement surgery"},{"name":"Treatment of acute deep vein thrombosis"},{"name":"Treatment of acute pulmonary embolism"},{"name":"Prophylaxis of thromboembolism in patients with acute coronary syndrome"}]},"trialDetails":[{"nctId":"NCT07299695","phase":"PHASE3","title":"Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis","status":"RECRUITING","sponsor":"Argyrios Tzouvelekis","startDate":"2026-01-25","conditions":"Idiopathic Pulmonary Fibrosis, Acute Exacerbation of Idiopathic Pulmonary Fibrosis","enrollment":196},{"nctId":"NCT04368377","phase":"PHASE2","title":"Enhanced Platelet Inhibition in Critically Ill Patients With COVID-19","status":"COMPLETED","sponsor":"University of Milan","startDate":"2020-04-06","conditions":"Pneumonia, Viral, Corona Virus Infection, Respiratory Failure","enrollment":5},{"nctId":"NCT00603824","phase":"PHASE4","title":"Fondaparinux in Patients With Acute Heparin-Induced Thrombocytopenia (HIT)","status":"WITHDRAWN","sponsor":"Methodist Healthcare","startDate":"2008-01","conditions":"Heparin-Induced Thrombocytopenia","enrollment":""},{"nctId":"NCT00064428","phase":"PHASE3","title":"OASIS-6 : The Safety and Efficacy of Fondaparinux Versus Control Therapy in Patients With ST Segment Elevation Acute Myocardial Infarction","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-08","conditions":"Thromboembolism","enrollment":12092},{"nctId":"NCT00476216","phase":"PHASE1","title":"Fondaparinux (Arixtra) With Chemotherapy for Advanced Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2007-09","conditions":"Non-Small Cell Lung Cancer, Venous Thromboembolism","enrollment":23},{"nctId":"NCT00464087","phase":"PHASE3","title":"Switching From Fondaparinux to Bivalirudin or Unfractionated Heparin in ACS Patients Undergoing PCI","status":"COMPLETED","sponsor":"Medstar Health Research Institute","startDate":"2007-06","conditions":"Acute Coronary Syndromes","enrollment":100},{"nctId":"NCT00328939","phase":"PHASE3","title":"ARIXTRA Local Study For Registration In China.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-05","conditions":"Thromboembolism, Knee Replacement, Hip Replacement","enrollment":240}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":30,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"ARIXTRA infusion","genericName":"ARIXTRA infusion","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Arixtra is an oligosaccharide used to treat conditions such as Non-Small Cell Lung Cancer, Venous Thromboembolism, and Acute Coronary Syndromes, often in combination with chemotherapy. It is administered through infusion, although specific dosing and administration details are not provided in the given facts.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}